INTRODUCTION
The congenital neutropenias are inherited hematologic conditions that are usually recognized in infancy or early childhood. Congenital neutropenia is often diagnosed when a young child has a differential white blood cell count performed for symptoms and signs of a severe infection. Congenital neutropenia may also be recognized in evaluating a child with a complex congenital syn drome. The severity of the neutropenia and its clinical consequences vary considerably.
Neutropenia is defined as an absolute blood neu trophil count more than 2 standard deviations below normaL The absolute count is percent neutrophils plus bands counted on a differential multiplied by the total white blood cell count Using this definition, the blood count to define neutropenia varies by age and race. In children 1 month to 10 years of age, neutropenia is defined by a neutrophil count less than 1500 cellS/ilL; beyond 10 years of age, neutropenia is defined by a neu trophil count less' than 1800 cells//1L in persons of white and Asian descent. 1 In persons of African descent, neu tropenia is defined by a count of 800--1000 cells//1L. 1 The severity and duration of neutropenia are also clin ically important. Mild neutropenia is usually defined by neutrophil counts of 1000-1500 cells//1L, moderate neu tropenia is 500-1000 cells//1L, and severe neutropenia is less than 500 cells//1L. Acute neutropenia usually is present for only 5-10 days; neutropenia is chronic if its duration is at least several weeks. Almost all congenital neutropenias are chronic neutropenia.
The characteristics and causes of congenital neu tropenia are shown in Tables 13-1 and 13-2, and an algo rithm for their diagnosis is presented in Figure 13 -1.
SEVERE CONGENITAL NEUTROPENIA
Patient'; with severe congenital neutropenia (SCN) typi cally present with recurrent bacterial infections and neutrophil count'> persistently less than 200 cells//1L. Kostmann described SCN as an autosomal recessive dis order in 1956 2 ; subsequently many sporadic cases and families with an autosomal dominant inheritance were reported. The incidence of SCN is estimated at 2 per 1 million births. 3
Pathophysiology
The genetics of SCN are heterogeneous. Up to 80 o /i! of patients have heterozygous mutations in exons 2, 3, 4, or 5 of the gene for neutrophil elastase (NE), also known as e1astase-2 (EL42; locus 19p13.3) 4,5 ( Fig. 13-2 ). ELA2 encodes a potent protease that is synthesized at the promyelocytic stage in neutrophil development and packaged in the neutrophil's primary granules. Genetic and cellular evidence is persuasive that mutations in ELA2 cause sporadic and autosomal dominant SCN. The 2 SEC T I 0 N1 DISEASES OF HEMATOPOIETIC CELL PRODUCTION cause for the autosomal recessive cases is still unknown, In autosomal dominant SCN, the same mutation is found in all affected family members but not in normal relatives. 6 In a very informative case, the father of a patient with typical SCK showed mosaic of the same ELA2 mutation; half of his somatic Wined the mutant gene, but the mutant was vir tually absent in circulating neutrophils. In this natural observation, neutrophils expressing the abnormal gene appeared to be destroyed in the marrow before the circulation,7 fIuman promyelocytic leukemia such as HL-60 cells, which express the neutrophil esterase mutants, exhibit accelerated apoptosis. 8 Accel erated apoptosis may be mediated through altered expression of Bcl-2 proapoptotic factors, which appear to be normalized with the administration of granulocyte colony-stimulating factor CG-CSF). 9 Several other muta tions have been associated with SCN, but their causal role is uncertain. G-CSF receptor mutations, which have been reported in a few cases, were probably acquired muta tions during evolution to acute myelogenous leukemia (AMi). 8,10 A mutation in CFII has been reported in one child. d
Clinical Features and Diagnosis
In addition to severe neutropenia, SCN patients usually have monocytOSis, thrombocytosis, and a mild normo normochromic, or hypochromic anemia. The bone marrow characteristically shows "arrest" of neutrophil development at the promyelocyte and myelocyte stage, although some samples show many maturing band and neutrophils, particularly in response to infec tions, The cellularity of the bone marrow is normal or with a reduced myeloid-to-erythroid ratiO, normal megakaryocytes, and occasional eosinophilia 3 Anemia and thrombocytOSiS are probably due to chronic inflammation; monocytosis may also reflect growth factor stimulation of the neutrophil-monocyte lineage. At diagnosis, tests for anti neutrophil antibodies and chromosomal abnormalities are negative,3 Tests for ELA2 mutations may be helpful but are still largely a research nr'.....r'~r1 ' Patients with SCK typically have recurrent fevers, and skin, respiratory, and perirec tissue abscesses in the liver and lungs with bacteremias are not uncommon, and these infec tions may become life-threatening. Common pathogens include aureus, Escherichia and Pseudomonas Until recently, SCN was often fatal as a result infections in early childhood, despite prompt and antibiotic therapy. Prior to the availability of the mortality by the age of 2 years was estimated at 42%.
Treatment and Prognosis
The availability of G-CSF has markedly changed the outlook for SCN Almost all patients respond to G-CSF with in their quality of life, lZ By contrast, corticosteroids, lithium, 15.16 intravenous
immunoglobulins, 17,18 or granulocyte-macrophage colony stimulating factor 19 are of little benefit The role of CCSF in the treatment of the congenital is summarized in Table 13 -3, The effectiveness phylactic G-CSF was established in a randomized, con trolled clinical trial. 20 In this study, the median G-CSF dose for SCN was approximately 5Jlg/kg/day; at this dose, G-CSF was increased by 5-10Jlg/kg/day every 14 days to achieve a neutrophil count greater than 1000 cells/JlL. Currently, dosages higher than 50-100Jlg/ kg/day are generally not recommended because of the low likelihood of benefit and the volume of drug required, 3, 21 Adverse effects are generally mild, primarily of transient headache and bone pain. 20 Splenomegaly, osteoporosis, vasculitis, rashes, arthralgia, and hematuria are infrequent adverse events. 22 Allogenic hematopoietic stem cell transplantation is the only estab lished alternative treatment for patients refractory to G-CSF.
SCN patients are at risk of developing myelodyspJas tic syndrome CMDS) and A\llL, a risk recognized before the of G-CSF. In a population of SCN patient transformation to AML or MDS occurred in about 2% per year. 24 The risk appears to be higher for with more severe disease, as reflected by of higher doses of G-CSF. 6 Monitoring clinical evaluations, blood counts, and an marrow examination is recommended to changes and chromosomal abnormali ties, the acquisition of monosomy 7. Ras and G-CSF receptor mutations also have been linked to malig nant transformation. 22 Survival after hematopoietic stem cell transplantation is more favorable if patients do not have MDS/AML; transplantation should be considered in patients transformation in their bone marrow.
CYCLIC NEUTROPENIA
Cyclic neutropenia usually with recurring episodes of fever, mouth ulcers, pharyngitis, and lym phadenopathy every 3 which usually resolve spontaneously over about 5-7 days. In 1910, Leale reported the first case in a 19-month-old boy.25 CN occurs sporadically or autosomal dominant inheri tance; the estimated is 0.5-1 per 1 million births, 26
Pathophysiology
Mutations of ~he gene for NE were originally implicated in autosomal dominant and sporadic forms of Cl'\ prior to the discovery of the same associa tion with SCN, ELA2 mutations predominantly involve exon 4 at its junction with intron 4 27 In both SCN and CN, the neutrophil are sub~ jected to accelerated apoptosis) marrow produc tion of neutrophils ineffective, The loci of the mutations predicted that they affect function of the active site of the enzyme binding to its substrates or to natural inhibitors, 4 No abnormality of the gene for the GCSF receptor or other genes has been documented in well-characterized cases of CN. (Fig. 13-4) . The bone marrow histol ogy varies cyclically. During neutropenia, there is "neu trophil maturation arrest" at the promyelocyte or myelocyte stage and the bone marrow may become "hyperplastic" during periods of neutrophil count recov ery, showing large numbers of marrow neutrophils (Fig. Tests for chromosomal abnormalities and anti neutrophil antibodies are negative, Mathematical studies suggest that cyclic oscillations in cells of the marrow and blood are a natural feature of hematologic diseases with increased apoptosis of early progenitors. : \0.31 The diagnosis of CN is primarily based on the char acteristic fluctuations of blood neutrophils in serial blood counts performed at least two to three times per week for weeks. Sequencing of ELA2 is available and may aid in the diagnosis, but serial blood counts remain important to determine diagnosis and prognosis. Family studies and ELA2 sequencing indicate that there are mild cases of CN with less severe neutropenia and fewer infections.
Clinical Features and Diagnosis
Fever, malaise, oral ulcers, and lymphadenopathy are features of almost every cycle in most cases; the mouth ulcers can be extremely deep and painful. Cellulitis, sinusitiS, pneumonia, mastoiditis, and recurrent perirec tal lesions are also common. Although CN is generally more benign than is SCN, about 10% of patients will die suddenly from peritonitis, necrotizing enterocolitis, and sepsis with Clostridium perfringens and E. coli bac teremias during a neutropenic period, 32
Treatment and Prognosis
Historically, the management of CN was suppOltive care, intermittent antibiotics, and good oral hygiene. Now treatment with prophylactic Cj·CSF decreases the sever ity of the neutropenia, shortens the periodicity, and pre vents recurrent infections. 33 A typical G..CSF dose is approximately 1~5 on a once-daily or every, other-day schedule. 34 Neutropenia may become less severe in adulthood, when the severity and frequency of infections wane; the mechanism underlying this change is not known. 35 Patients with CK have no recognized risk of transforma tion to MDS or AIvlL, with or without G-CSF treatment.
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MYELOKATHE.XIS AND WHIM SYNDROME
Myelokathexis term for retention of neutrophils in the bone marrow) is a rare congenital disorder characterized by severe neutropenia and lymphocytopenia, first described by Zuezler and by Krill and colleagues in 1964,36,37 White blood cell counts are usually less than 1000 cells!~L, and neutrophil counts less than 500 cellS/ilL. The neutrophils in the blood and marrow have very pyknotic nuclei, a distinctive if not entirely diag nostic feature of this disorder, Neutropenia associated with wafts, hypogammagiobulinemia, infections, and myelokathexis constitute the WHIM syndrome. Both myelokathexis and WHIM syndrome have autosomal dominant inheritance,38 although sporadic cases have also been reported. The genetic defect for WHIM syn drome has been isolated to the gene encoding a chemokine receptor (CXCH4) at chromosome 2q21.
Pathophysiology and Clinical Features
Diagnosis of myelokathexis is established by examina tion of the blood smear and bone marrow. The marrow is hypercellular with many neutrophil precursors, despite the abnormally low peripheral count. In the blood and bone marrow, neutrophils are characterized by hyper segmentation of their nuclear lobules separated by thin filaments of chromatin; they contain cytoplasmic vac uoles and prominent granules 40 ( Fig. 13-6 ). There is accelerated apoptosis of marrow and blood neutrophils, and their marrow precursors, attributable to depressed expression of bel-x. 40 Eosinophils can also appear bizarre, but the lymphocytes, monocytes, and basophils typically appear normal. Killing of bacteria by the neu trophils is normal. 41 Immune function may be primarily affected as a result of abnormal surveillance and traf ficking of leukocytes, functions mediated through the CXCR4 receptor and its interactions with CXCLl2 (stromal-derived factor-1 a.).
Treatment and Prognosis
Despite severe neutropenia and lymphocytopenia, serious bacterial infections are very infrequent. Patients with WHI1\1 syndrome have susceptibility to human papi! lomavirus but not to cytomegalovirus or Toxoplasma gondii, Treatment with G-CSF partially corrects the ac celerated apoptosis of developing neutrophils 40 and normalizes blood neutrophil levels, increases immunoglobulin levels, and may reduce infections. 43 8
However, for most patients, this treatment is not necessary.
CARTIIAGE·HAIR HYPOPlASIA
Cartilage-hai:" hypoplasia (CHH) is a rare autosomal recessive disorder characterized by a short-limb dwarfism, hypoplastic hair, and impaired T-cell function ,'lith a susceptibility to viral infections, especially vari cella-zoster. It was first described by McKusick and
cowOIkers in 1965 in an isolated Old Order Amish com munity.44 In Finland, the incidence of CBH is ] : 23,000. 45 Among the Old Order Amish, an isolated religious com munity, the incidence has been estimated at 1.5:] 000. Sporadic cases have been described in many other ethnic populations.
Pathophysiology
The genetic defect of CHH is located at locus 9p13, where mutations to the gene encoding the ribonuclease MRP have been identified. 48 Ribonuclease MRP is an endoribonuclease that cleaves RNA or pre-ribosomal RNA in mitochondrial processing. CHH is associated with increased apoptosis of T lymphocytes with altered expression of Fas and Bax, members of the Bcl-2 protein family. 49 There is remarkable variability of expression among members of affected families, suggesting that other modifying factors play a role in the expression of the CHH phenotype.
Clinical Features
In a study of 88 Finnish patients, 86% had macrocytic anemia, 62% had lymphopenia, and 24% had variable degrees of neutropenia. 50 Rare cases were associated with fatal hypoplastic anemia. Skeletal biopsies have shown cartilage hypoplasia, typically manifested as short ened limbs with increased joint laxity. The hair is characteristically fine, fragile, and sparse, and typically light-colored. Other associated features include Hirschsprung's disease (colonic aganglionosis) 51 and malignanCies (lymphoma and basal cell carcinoma). 52 Between 1971 and 1995, a population register center in Finland documented that the most frequent causes of death were pneumonia and sepsis.
Treatment and Prognosis
Hematopoietic stem cell transplantation corrects the immunodefiCiency, but not the chondrodyplasia. 54 Treat ment of four patients with growth hormone was without benefit. 55
SHWACHMAN-DIAMOND SYNDROME
Shwachman-Diamond syndrome (SDS) is a rare autoso mal recessive disorder characterized by pancreatic insuf ficiency, neutropenia, and sholt stature. Shwachman and associates first described the syndrome in 56 The incidence of this disorder is 1: 77,000, with approxi mately 300 cases repolted as of December 2000. 58
Pathophysiology
The genetic defect is located at 7qll at a site now des ignated the SBDS CShwachman-Bodian-Diamond syn~ drame) gene. 60 Although the mutations in SBDS are not understood, indirect evidence points to abnormal RNA metabolism that could widely affect cellular function in the pancreas, bone marrow, and bone. 60 The connection between these genetic mutations and the phenotypiC expression of the cellular abnormalities has not been established. Cellular manifestations include defects in neutrophil chemotaxis 61 and abnormalities of progenitor cells in the bone marrow, which have a decreased poten tial to form new colonies and an increased apoptosis rate. 62
Clinical Features and Diagnosis
Neutropenia is seen in virtually all patients, approxi mately 66% have neutrophil counts less than 1000 cells/l-lL, and cyclic fluctuation is common. 58 Cellulitis, otitis media, pneumonia, and osteomyelitis are associated with the neutropenia. Mild normochromic and normo cytic anemia occurs in 80% of cases. 58 Thrombocytope nia occurs frequently (24-88% of cases), with recorded fatal hemorrhagic events. 58 Cell-mediated immunity also can be impaired. 63 As many as one third of patients with SDS undergo malignant transformation to MDS and AML, with acquired clonal chromosomal abnormalities. 61 SDS is a multisystem disorder with variable involve ment of other organ systems, including the pancreas, liver, kidneys, and teeth. Malabsorption resulting from pancreatiC insuffiCiency is often severe, particularly in young children. Growth problems occur in the first 2 years; metaphysial chondrodysplasia, metaphyseal dysos tosis, rib cage abnormalities, syndactyly, kyphosis, and scoliosis are also common features.
Diagnostic criteria for SDS include evidence of pan creatic insuffiCiency and the hematologic abnormalities. 58 Pancreatic insufficiency can be established by an elevated 72-hour fecal fat level, a decrease in serum cationic trypsinogen, and an abnormal quantitative pancreatic stimulation test. The hematologic abnormalities are man ifested by neutropenia (absolute neutrophil count < 1500 [ cells/I-lL), anemia (hemoglobin ~than 2 standard devi-t ations below the age-adjusted nean), and thrombocy topenia (platelet count < 150,000 ells/mm 3 ).
Treatment and Prognosis
Supportive therapy includes pancreatic enzyme replace ment and antibiotic therapy for infections. Case studies havehslhown t~at G-CSF is effhective in increasing ~h~. neu-~ trop I count m patients WIt severe neutropema" and Ii also in decreasing the rate of infections. ~DS patients with aplastic anemia may respond to cbrt1tosteroids 66 and cyclosporine therapy. 67 The only curative treat ment following malignant transformation is a stem cell transplant 68 The role of annual bone marrow evaluation in 10ng term follow-up of patients with SDS is controversiaL Frequent marrow examinations monitor for acquired chromosomal abnormalities, which may precede malig nant transformation, but some abnormal clones may regress without intervention. 69 If patients with SDS in fact survive the respiratory difficulties and the most serious infections of early life, both the neutropenia and the pancreatic insufficiency may wane as they age. However, aging also increases the risk for undergoing malignant transformatIon to MDS and A.\;1L. The projected median survival of patients is more than 35 years. 58
CHEDIAK-HIGASHI SYNDROME
Chediak~Higashi syndrome (CBS) is a rare autosomal recessive disorder characterized by hypopigmentation of the hair, eyes, and skin; giant granules in several types of cells; and neutropenia with recurrent bacterial infec tions. CHS was first reported by Beguez-Cesar in 1943 70 and further defined by Chediak, Higashi, and Sato. 7~ About one half of all cases with CBS are now attributa ble to mutations of the CHSl gene at lq43 that encodes a lysosomal trafficking regulatory protein (LYST). 74 Muta tiems of CHSl that totally abolish LYST expression cause more severe disease; milder cases are associated with missense mutations.
Clinical Features and Diagnosis
CHS is diagnosed by detection of the giant granules in neutrophils, monocytes, and lymphocytes, which are easily visible by light microscopy and are sometimes more prominent in the bone marrow than in the blood. In neutrophils, the very large granules appear to result from fusion of the primary and specific granules ( Fig.  13-7) .
These cells undergo intramedullary destruction resulting in neutropenia. Blood neutrophils have depressed chemotaxis 78 and diminished bactericidal potency.79 Platelet'> also have abnormal granules and exhibit defective aggregation leading to easy bruising and bleeding. 80 • s ; Cytotoxic T-cell and natural killer cell func tion are also abnormal.
In the most common and severe form, young children develop recurrent, often life threatening, bacterial infections and then progress in an "accelerated phase,"84 characterized by diffuse lym phohistiocytic infiltration of the liver, spleen, lymph nodes, and bone marrow, and progressively worsening pancytopenia.
Treatment and Prognosis
Management is directed primarily to avoiding infections and appropriate institution of antibiotic treat ment. Ascorbic acid improves neutrophil functions in vitro,85 but its clinical benefits are uncertain. 86 . 87 G-CSF may increase blood neutrophils but is also an unproven therapy. 8t:~ystemic corticosteroids have been used to treat an a't:companying peripheral neuropathy.89 Treat ment of the accelerated phase with vincristine and corti costeroids can induce temporary remissions, but bone marrow transplantation is the only known cure. 90
GRISCELLI SYNDROME
In 1978, Griscelli and colleagues described two patients with hypopigmentation of the hair and skin, similar to CHS, but with normal-appearing neutrophils. 91 The three subtypes of this rare autosomal recessive disorder occur predominantly in persons of Turkish and Mediterranean descent. 92 In type 1, attributable to a mutation in the M~05a gene at 15q21 (expressed 
Clinical Features and Diagnosis
Based on the phenotypic similarities between Griscelli syndrome and CHS, a patient with hypopigmentation and immune dysfunction should be evaluated for both con ditions. The distinguishing feature of CHS is the presence of large granules in the neutrophils, melanocytes, and keratinocy'tes. Examination of the hair shafts in patients WIth CHS shows only small melanin aggregates in com parison to the large clumps seen inpatients with Griscelli syndrome. Because of the defect in granule transport, melanosomes accumulate in the melanocytes but are reduced in the keratinocytes in all subtypes of Griscelli syndrome. 98 Confirmation can be provided by mutation analysis.
. Patients with Griscelli syndrome have silver hair with hypopigmentation of their skin and eyes. Patients with type 2 are vulnerable to fever and recurrent infections. Hepatosplenomegaly and a combined T-cell and B-cell defiCiency are common. Natural killer cell'\ activity delayed-type hypersenSitivity, and the response to -~ antigenic challenge all are impaired. 99 Immunoglobulin. levels may be normal or low; other features are hy rinogenemia, hypertriglyceridemia, and hypoproteine mia. 99 The accelerated phase with hemophagocytic lymphohistiocytosis is characterized by fever, pancy topenia, and diffuse lymphocytic infiltration of brain spleen, liver, and lymph nodes. Neurologic deficits ar~ associated with lymphohistiocytic infiltration in the central nervous system. 95
Treatment and Prognosis
The accelerated phase is lethal within months without a hematopoietic stem cell transplantation, although immune suppression with glucocorticosteroids, anti thy mocyte globulin, methotrexate, etopOSide, and cyclosporin have all been reported to be of benefit, at least transiently. 101-!O3 _ _ 6 SEC T ION:1 DISEASES OF HEMATOPOIETIC CELL PRODUCTION BARTH SYNDROME Barth syndrome is rare disorder characterized by car diomyopathy, neutropenia, and skeletal myopathy, In 1 Barth and associates described a large family with affected males who typically died from sepsis or cardiac failure before the age of 3,104 Mitochondria appeared normal in cardiac and skeletal muscle, A patient with a similar X-linked condition, reported by Neustein and coworkers in 1979, had abnormal mitochondria on elec tron microscopy. 105 Barth syndrome has an estimated incidence of 1 per 300,000--400,000 male births, based on the identification of 10 new cases annually in the enited States, 106
Pathophysiology
The locus for the Barth syndrome gene is Xq28, 107 and the disease is due to mutations to the G45 gene (renamed TAZ), 108 The gene products of 7.t42, the tafazz ins, may share some homolob'Y with acetyltransferases involved in complex lipid metabolism, 109 and defects in cardiolipin synthesis may lead to mitochondrial dysfunc tion, 110 Molecular abnormalities of several phospho lipids, including cardiolipin, were demonstrated in 19 of 25 children with Barth syndrome. 111
Clinical Features and Diagnosis
Barth syndrome findings include dilated cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and elevated urinary excretion of 3-methylglutaconic acid. Diagnosis is established by echocardiogram, quantitative urine organic acid analysis including quantification of 3 methylglutaconic acid (can be increased 5-to 20-fold), serial blood counts, and growth monitoring. 106 Neu tropenia can be chronic, cyclic, or absent. 112 Cyclic oscil lations in Barth syndrome occur at between 21 and 28 days. Peak absolute neutrophil counts are often normal, and nadirs approach zero, During infections, the neu trophil count may rise to normal or high levels.
Treatment and Prognosis
Supportive therapy is critical. Early diagnosis of Barth syndrome has been correlated with improved survivaL 106 Cardiac function improves and may be normalized by treatment of congestive heart failure. Infectious compli cations improve with prompt recognition and aggressive treatment. G-CSF increases neutrophil levels and may be clinically beneficiaL ,06 6
GLYCOGEN STORAGE DISEASE, TYPE lb
Glycogen storage diseases are genetic disorders that interfere with glycogen syntheSiS and degradation, Glycogen storage disease (GSD) was first described by 
Clinical Features and Diagnosis
Patients with GSD Ib typically present with hypo glycemia, hepatomegaly, and growth retardation early in the first year of life.
Deficiency of the glucose 6 phosphate translocasecauses hypoglycemia with irri tability, seizures, and coma. Other features include hyperlipidemia, hypemricemia, organomegaly secondary to glycogen accumulation, inflammatory bowel disease, and osteopenia.
The diagnosis of GSD Ib is established based on clin ical features and the absence of an increase in semm glucose levels follOWing the administration of glucagon or oral galactose. Mutation analysis and enzyme studies on samples obtained by open liver biopsy can confirm the diagnosis. 124 About 90% of patients have neutrophil counts of less than 1000 cells/IJ-L 125 at diagnOSiS, and usu-ally the neu tropenia gradually worsens. 125 Patients may also be anemic and experience frequent epistaxiS. 124 The bone marrow may be normal or hypercellular with abundant mature neutrophils, or may show "maturation arrest." 126, 127 Marrow neutrophils appear predisposed to early apoptosis. 128 Neutropenia plus neutrophil dysfunc tion, reduced chemotaXiS, and impaired respiratory burst 118, 129, 130 result in susceptibility to infections of the skin and perioral and perianal areas as well as pneumo nia, sepsis, and meningitis. Infections are often caused by Staphylococcus aureus, group A streptococci, Strep tococcus pneumoniae, E. coli, and Pseudomonas species. 127 Chronic diarrhea and inflarrunatory bowel disease are often severe, In these neutropenic patients, it may be difficult to determine whether new gastroin testinal symptoms represent a worsening of chronlC inflammatory conditions or a new infection. Late com plications of GSD 1b include predisposition to hepatic adenomas with increasing age and progressive renal disease. 124 The relationship between neutropenia and inflammatory bowel disease is unclear, Bl Neutrophil function and counts may improve follOWing portacaval shunt anastomosis 132 and liver transplantation, 133, 134 
Treatment and Prognosis
Treatment is directed toward correcting the metaholic abnormalities, as well as prevention of hypoglycemia and seizures. Liver transplantation is indicated in patients with dietary-unresponsive metaholic control and with compli cations of hepatic adenomas, including hemorrhage, compression, or malignant transformation. 12,1 <;J~ §;SF cor rects the neutropenia and reduces infectiorlspsplenic enlargement is a universal complication of cytokine administration.
Low doses should be used, starting at 1--2Ilg/kg/day to maintain neutrophils at tOOO-2000/mmo. 156 The inflammatory bowel disease also improves with G-CSF treatment.
WISKOTT·ALDRICH SYNDROME
Wiskott-Aldrich syndrome (WAS) is characterized by microthrombocytopenia, immunodeficiency, and eczema. The first case was first described by Wiskott in 1937,137 and X-linked inheritance was reported by Aldrich and colleagues in 1954.138 The clinical manifes tations of WAS are variable, and its phenotypic expres sion may evolve over time. In addition to an increased susceptibility to recurrent infections, patients are at risk to develop autoimmune disorders and malignancies. In its most henign form, X-linked thrombocytopenia, patients have low platelet counts «70,OOO/mm3) and abnormally small platelets, but do not manifest the immunologic abnormalities. Rarely, isolated neutropenia can he the presenting feature of WAS.
WAS occurs with a frequency of 4 per 1 million males. 1<;0
Pathophysiology
The WAS protein (WASP) gene is located at Xpl1.22-·pl1.23. 141 More than 150 unique mutations have heen reported in over 340 families. 142 The wide range of genotypic manifestations likely correlates with the variability of phenotypiC expression. Patients who lacked ~VASP gene expression (those with nonsense mutations, deletions, small deletions, and small insertions) were found to have an increased risk to develop infections, severe eczema, intestinal bleeding, and malignancies; these null expressions were predictive of mortality and morbidity. 143 The gene product of WASP is a cytoplasmic scaffolding protein that stabilizes actin filaments. The protein is believed to be important in the actin cytoskeletal rearrangement that occurs in response to immunoreceptor stimulation. ;44
Clinical Features and Diagnosis
A review of 154 patients revealed that only 27% had the classic triad of microthrombocytopenia, bloody diarrhea, and eczema; hematologic manifestations were present in 20% before the diagnosis of WAS was estahlished. The clinical course was quite variable, even among patients in the same kindred. Autoimmune complications were associated with the risk of future malignancy. 145 Neu~ CHAPTER 13 CONGENITAL NEUTROPENIA tropenia, probably on an autoimmune basis, occurs in up to 25% of patients.
Other autoimmune processes (arthritis, skin vasculitis, cerebral vaSCUlitis, inflammatory bowel disease, and glomerulonephritis) are also common in early childhood. 146 
Treatment and Prognosis

Congenit",1 Neutropenia
• The molecular pathophysiology hnking the genetic defects associated with the. diseases that cause con genital neutropenia to their phenotypic expression remainsunderinve$tigation,
• The molecular pathophysiology must fora wide spectrum ofphellotypkexpressionseen with. the diseases that Cause congenital m";utropenia.
• The risk leukemic transforrrtation varies substan tially in various types of congenitalneutrbpenia. Risk factors for leukemia are not yetfully defined,
• future treatment ofcongenital neutropenia may be directed at .correcting underlying genetic defects or may include drugs specifically designed to target abnormal molecular pathways Periodic oscillations of neutrophil counts, with nadirs <200 celIS/ilL approximately every 21 days and periodic vulnerability to infections, especially oral ulcerations, Neutrophil counts <500 cellS/ilL with lymphopenia despite hypercellular bone marrow, Neutrophils and eosinophils appear "bizarre" in bone marrow and blood. Association of warts, hypogammaglobulinemia, infections, and myelokathexis (retention in the bone marrow) defmes WHLY.l syndrome, Short-limb dwarfism with hypoplastic hair, T-cell dysfunction, Neutropenia seen in -24% of cases. ExoQ"ine pancreatic dysfunction, short stature, and neutropenia (66% with absolute neutrophil count <1000 cells/f,lL, often with cyclic fluctuations), mild anemia, . Hypopigmentation of hair, and skin with neutropenia and recurrept bacterial infections. Giant peroxidase-positive lysosomal granules in granulocytes from bone marrow and blood, Vulnerability to hemophagocy1ic lymphohistiocytosis evolution, Hypopigmentation of hair and skin, neutropenia typically seen in assodation with pancytopenia: patients also have impaired T-cell and B-cell function, Vulnerability to hemophagocytic lymphohistiOcy10sjs evolution, Cardiomyopathy, skeletal myopathy, and neutropenia(can be cyclic), Abnormal skin pigmentation, nall dystrophy, and mucosal leukoplakia. Bone marrow failure before the first decade of life is common with pancytopenia, Hypoglycemia, hepatomegaly, and grm"lth retardation associated with glycogen accumulation in the liver and kidneys, Neutrophil counts typically <1000 cellS/ilL; neutrophil dysfunction, Microthrombocytopenia, immunodeficiency (25% with neutropenia), and eczema; increased risk of autoimmune disease and malignancy.
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